Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A Systematic Review and Single-Arm Meta-analysis.
Fernanda Ferreira BomtempoRebeka Bustamante RochaGiulia Isadora CenciGabriela Borges NagerJoão Paulo Mota TellesPublished in: Clinical drug investigation (2022)
Erenumab has a favorable safety profile, with a low incidence of serious AEs, and sustained efficacy over ≥1 year of follow-up in the treatment of migraine.